Elahere and Keratitis - a phase IV clinical study of FDA data

Summary:

Keratitis is reported as a side effect among people who take Elahere (mirvetuximab soravtansine-gynx), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Crestor, and have Ovarian cancer.

The phase IV clinical study analyzes which people have Keratitis when taking Elahere. It is created by eHealthMe based on reports of 479 people who have side effects when taking Elahere from the FDA, and is updated regularly.

What is Elahere?

Elahere has active ingredients of mirvetuximab soravtansine-gynx. eHealthMe is studying from 479 Elahere users. Check the latest studies of Elahere.

What is Keratitis?

Keratitis (eye's cornea, the front part of the eye, becomes inflamed) is found to be associated with 414 drugs and 838 conditions by eHealthMe. Check the latest studies of Keratitis.

On Jul, 29, 2026

479 people reported to have side effects when taking Elahere.
Among them, 22 people (4.59%) have Keratitis.

Among these 22 people:

How long have people been on Elahere when they have Keratitis? *

What is the gender of people who have Keratitis when taking Elahere? *

female: 100 %
male: 0.0 %

What is the age of people who have Keratitis when taking Elahere? *

What are other drugs people take besides Elahere? *

Zofran: 1 person, 4.55%
Pred Forte: 1 person, 4.55%
Miralax: 1 person, 4.55%
Crestor: 1 person, 4.55%

What are other side effects people have besides Keratitis? *

Keratopathy (noninflammatory disease of the cornea): 4 people, 18.18%
Neuropathy Peripheral (surface nerve damage): 3 people, 13.64%
Nausea (feeling of having an urge to vomit): 2 people, 9.09%
Visual Acuity Reduced (reduced clearness of vision): 1 person, 4.55%
Vision Blurred: 1 person, 4.55%
Pneumonia: 1 person, 4.55%
Photophobia (extreme sensitivity to light): 1 person, 4.55%
Hordeolum (small collection of pus (abscess) on the eyelid): 1 person, 4.55%
Headache (pain in head): 1 person, 4.55%
Dry Eyes (lack of adequate tears): 1 person, 4.55%

What are the existing conditions these people have? *

Ovarian Cancer (cancer of ovary): 5 people, 22.73%
Ovarian Cancer Recurrent (reoccurrence of ovary cancer): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Elahere and have Keratitis?

- Check whether Keratitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Elahere:

Elahere (479 reports)

Keratitis treatments and more:

Keratitis (4,120 reports)

How severe was Keratitis and when was it recovered:

Keratitis in Elahere

Expand to all the drugs that have ingredients of mirvetuximab soravtansine-gynx:

Keratitis and drugs with ingredients of mirvetuximab soravtansine-gynx

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Elahere:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Keratitis:

Keratitis (414 drugs)

Browse all the conditions that are associated with Keratitis:

Keratitis (838 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mirvetuximab soravtansine-gynx (the active ingredients of Elahere) and Elahere (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.